Compare NICE Ltd (NICE) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Novavax Inc — how do they compare? NICE Ltd trades at $99.51 (market cap $5.94B), while Novavax Inc trades at $9.86 (market cap $1.62B). The key difference: NICE Ltd is far larger — about 3.7× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| NICE | NVAX | |
|---|---|---|
Market Cap | $5.94B | $1.62B |
Sector | Technology | Health |
52-Week High | $153.44 | $11.19 |
52-Week Low | $83.15 | $6.22 |
Enterprise Value | $5.68B | $1.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE stock trades at $101.47, down 3.82% in the last session, with a bearish technical signal but strong fundamentals. The company reported Q2 2026 revenue growth of 7.6% and beat EPS estimates, with cloud and AI revenue surging. Recent news highlights customer wins with AOK PLUS and Bluecrest on its CX AI platform, reinforcing its market position. Valuation metrics appear attractive with a P/E of 14.4 and EV/EBITDA of 6.59, suggesting potential undervaluation.
The outlook is positive due to robust earnings beats, raised 2026 EPS guidance to $11.06–$11.26, and analyst consensus price target of $118.67 implying 17% upside. Risks include near-term earnings headwinds and competitive pressures in the CX software space. Institutional buying by firms like Bank of America supports bullish sentiment, though technical indicators signal caution with resistance at $103.
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
